Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain

Other authors

[López de Rioja V, Perramon-Malavez A, López D, Prats C, Alvarez-Lacalle E] Department of Physics, Universitat Politècnica de Catalunya, Castelldefels, Barcelona, Spain. [Basile L, Medina Maestro S] Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Martínez-Solanas É] Agència de Qualitat I Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Coma E, Fina F] Sistema d'Informació dels Serveis d'Atenció Primària, Institut Català de la Salut (ICS), Barcelona, Spain. [Mendioroz Peña J] Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Universitat de Vic - Universitat Central de Catalunya (UVic-UCC), Vic, Spain

Departament de Salut

Publication date

2024-05-22T07:59:55Z

2024-05-22T07:59:55Z

2024-04-27



Abstract

Òmicron; Covid-19; Impacte de la vacuna


Ómicron; Covid-19; Impacto de la vacuna


Omicron; Covid-19; Vaccine Impact


In the current COVID-19 landscape dominated by Omicron subvariants, understanding the timing and efficacy of vaccination against emergent lineages is crucial for planning future vaccination campaigns, yet detailed studies stratified by subvariant, vaccination timing, and age groups are scarce. This retrospective study analyzed COVID-19 cases from December 2021 to January 2023 in Catalonia, Spain, focusing on vulnerable populations affected by variants BA.1, BA.2, BA.5, and BQ.1 and including two national booster campaigns. Our database includes detailed information such as dates of diagnosis, hospitalization and death, last vaccination, and cause of death, among others. We evaluated the impact of vaccination on disease severity by age, variant, and vaccination status, finding that recent vaccination significantly mitigated severity across all Omicron subvariants, although efficacy waned six months post-vaccination, except for BQ.1, which showed more stable levels. Unvaccinated individuals had higher hospitalization and mortality rates. Our results highlight the importance of periodic vaccination to reduce severe outcomes, which are influenced by variant and vaccination timing. Although the seasonality of COVID-19 is uncertain, our analysis suggests the potential benefit of annual vaccination in populations >60 years old, probably in early fall, if COVID-19 eventually exhibits a major peak similar to other respiratory viruses.


This research was supported by the Ayudas Fundación BBVA a proyectos investigación científica 2021 under the project BBVA: Epidemiological modelling of SARS-CoV-2 in a post-pandemic surveillance context: an open platform for mid-term scenarios and short-term predictions; the Agència de Gestió d’Ajuts Universitaris i de Recerca, Catalonia [grant number 2021 SGR 00582]; and PID-2022- 139216NB-I00 funded by Ministerio de Ciencia e Innovación (MCIN/ AEI/10.13039/501100011033) and by ‘ERDF: A way of making Europe’, by the European Union.

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

Vaccines;12(5)

https://doi.org/10.3390/vaccines12050466

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)